Blazing New Paths
For Life Enhancing Treatments

Our BoNT/E product candidates

Our pipeline is comprised of two BoNT/E product candidates. Our therapeutic product candidate, EB-001T, is being developed for the treatment of focal muscle pain, localized pain that can be caused by muscle contractions and spasms, for which there are currently no approved therapies. Our aesthetic product candidate, EB-001A, is being initially developed for glabellar frown lines and scar reduction following Mohs micrographic surgery, or Mohs surgery.

News and Information

Allergan to Acquire Bonti Adding New Neurotoxin Programs to Medical Aesthetics Pipeline

September 14th, 2018|

Acquisition Adds Fast-Acting Neurotoxin Programs with 2 to 4-Week Duration to Allergan’s Best-in-Class Medical Aesthetics Portfolio and Pipeline

DUBLIN, IRELAND and NEWPORT BEACH, CA – SEPTEMBER 14, 2018 – Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced it has agreed to acquire Bonti, Inc., a privately held clinical-stage […]

Bonti Announces Presentation Featuring EB-001A at Masters of Aesthetics Symposium

August 23rd, 2018|

Dr. Jean Carruthers to Highlight Key Aesthetic Clinical Study Results for This Novel Neurotoxin with a Unique Clinical Profile

Bonti, a privately-held, clinical-stage biotechnology company, today announced a presentation featuring Phase 2a clinical results for its aesthetic product, EB-001A, at the 5th Annual Masters of Aesthetics Symposium on Friday, August 24th […]

Bonti Announces Successful Completion of Phase 2a Scar Reduction Clinical Study

August 2nd, 2018|

SHINE-1 Results Suggest EB-001A May Improve Appearance of Scars

Bonti, a privately-held, clinical-stage biotechnology company, today announced the topline results of its SHINE-1 Phase 2a clinical trial, the first clinical trial in its SHINE (Scar Healing Improvement with Neurotoxin E) clinical program, aimed at scar reduction. SHINE-1 evaluated EB-001A, Bonti’s aesthetic […]

Read Articles